Sorensen Grith L, Bladbjerg Else Marie, Steffensen Rudi, Tan Qihua, Madsen Jens, Drivsholm Thomas, Holmskov Uffe
Department of Cancer and Inflammation, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Unit for Thrombosis Research, Department of Public Health, University of Southern, Denmark; Department of Clinical Biochemistry, Hospital of Southwest Denmark, Esbjerg, Denmark.
Atherosclerosis. 2016 Mar;246:7-12. doi: 10.1016/j.atherosclerosis.2015.12.037. Epub 2015 Dec 29.
Surfactant protein D (SP-D) is a defense collectin with inflammation-modulating properties. SP-D deficiency inhibits atherosclerosis in vivo, and the circulatory SP-D levels have been previously associated with cardiovascular disease mortality. We hypothesized that plasma SP-D (pSP-D) and SP-D gene (SFTPD) single nucleotide polymorphisms (SNPs) are risk factors for atherosclerosis.
We evaluated individuals who were all 60 years old and participated in The Glostrup Population Study. Subclinical atherosclerosis was diagnosed based on the ultrasonographic measurement of intima-media thickness (IMT) and protruding plaques in the right carotid artery. Associations between cardiovascular traits and the levels of pSP-D (n = 687) or two coding SFTPD SNPs rs3088308 and rs721917 (n = 396) were investigated using multiple linear regressions and logistic regressions.
There was no significant association between pSP-D and the presence of plaques or IMT. The SFTPD SNP rs3088308 was nominally associated with the presence of plaques, and rs721917 was nominally associated with IMT. The directions of effects of associations were markedly dependent on current smoking status.
The results do not support that pSP-D levels influence the development of subclinical atherosclerosis. However, the SFTPD SNP data support previous observations from animal studies that SP-D plays a role in the etiology of atherosclerotic disease development. The nominal significant effects are likely to be mediated by structural variant SP-D modulation of effects of tobacco smoking and are independent of pSP-D levels. The data warrant confirmation in larger cohorts.
表面活性蛋白D(SP-D)是一种具有炎症调节特性的防御凝集素。SP-D缺乏在体内可抑制动脉粥样硬化,且循环中的SP-D水平此前已与心血管疾病死亡率相关。我们推测血浆SP-D(pSP-D)和SP-D基因(SFTPD)单核苷酸多态性(SNP)是动脉粥样硬化的危险因素。
我们评估了所有60岁且参与格罗斯特鲁普人群研究的个体。基于右颈动脉内膜中层厚度(IMT)的超声测量和突出斑块诊断亚临床动脉粥样硬化。使用多元线性回归和逻辑回归研究心血管特征与pSP-D水平(n = 687)或两个编码SFTPD SNP rs3088308和rs721917(n = 396)之间的关联。
pSP-D与斑块存在或IMT之间无显著关联。SFTPD SNP rs3088308与斑块存在名义上相关,rs721917与IMT名义上相关。关联效应的方向明显取决于当前吸烟状况。
结果不支持pSP-D水平影响亚临床动脉粥样硬化的发展。然而,SFTPD SNP数据支持先前动物研究的观察结果,即SP-D在动脉粥样硬化疾病发展的病因中起作用。名义上的显著效应可能由吸烟效应的结构变异SP-D调节介导,且独立于pSP-D水平。这些数据有待在更大的队列中得到证实。